| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.02▲ | 1.02▲ | 1.02▲ | 1.02▲ | 1.06▼ |
| MA10 | 1.01▲ | 1.01▲ | 1.01▲ | 1.02▲ | 1.07▼ |
| MA20 | 1.02▼ | 1.02▼ | 1.02▲ | 1.05▼ | 1.06▼ |
| MA50 | 1.02▼ | 1.02▼ | 1.03▼ | 1.07▼ | 1.19▼ |
| MA100 | 1.04▼ | 1.06▼ | 1.08▼ | 1.07▼ | 1.65▼ |
| MA200 | 1.09▼ | 1.10▼ | 1.08▼ | 1.11▼ | 10.66▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | 0.001▲ | 0.002▲ | -0.004▼ | 0.013▲ |
| RSI | 49.810▼ | 49.866▼ | 49.498▼ | 44.116▼ | 42.890▼ |
| STOCH | 51.944 | 48.232 | 48.232 | 41.181 | 52.730 |
| WILL %R | -60.000 | -63.636 | -63.636 | -71.526 | -55.014 |
| CCI | 7.527 | 14.347 | 14.347 | -31.167 | -47.399 |
|
Tuesday, September 22, 2026 05:00 PM
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp.
|
|
Monday, September 14, 2026 11:03 PM
King of Prussia, Pennsylvania Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA ...
|
|
Saturday, September 12, 2026 06:39 AM
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 Phio Pharmaceuticals ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/09/26 | 1.02 | 1.02 | 1.02 | 1.02 | 64,552 |
| 23/09/26 | 1.02 | 1.03 | 1.0001 | 1.02 | 75,153 |
| 22/09/26 | 1.02 | 1.05 | 0.99 | 1.00 | 204,069 |
| 21/09/26 | 1.04 | 1.05 | 1.00 | 1.01 | 78,511 |
| 18/09/26 | 1.04 | 1.06 | 1.01 | 1.03 | 156,550 |
| 17/09/26 | 1.03 | 1.0397 | 0.9883 | 1.02 | 79,376 |
| 16/09/26 | 1.00 | 1.02 | 0.9782 | 0.9991 | 53,360 |
| 15/09/26 | 1.04 | 1.04 | 0.99 | 1.02 | 114,343 |
| 14/09/26 | 1.03 | 1.05 | 1.01 | 1.03 | 67,204 |
| 11/09/26 | 1.03 | 1.05 | 1.025 | 1.03 | 94,416 |
|
|
||||
|
|
||||
|
|